POAI Insider Trading

Insider Ownership Percentage: 0.76%
Insider Buying (Last 12 Months): $126,796.00
Insider Selling (Last 12 Months): $0.00

Predictive Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at Predictive Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Predictive Oncology Share Price & Price History

Current Price: $0.40
Price Change: Price Increase of +0.0144 (3.77%)
As of 09/26/2022 03:11 PM ET

This chart shows the closing price history over time for POAI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Predictive Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2022Daniel E HandleyDirectorBuy2,550$0.37$943.5049,666View SEC Filing Icon  
5/24/2022J Melville EngleDirectorBuy159,500$0.37$59,015.00203,393View SEC Filing Icon  
5/20/2022Charles Lee Sr Nuzum SrDirectorBuy200,000$0.31$62,000.00286,164View SEC Filing Icon  
5/20/2022Robert L MyersCFOBuy16,125$0.30$4,837.5039,336View SEC Filing Icon  
10/22/2020Carl I SchwartzCEOSell640$0.85$544.001,611,341View SEC Filing Icon  
9/1/2020Richard L GabrielDirectorBuy4,000$0.90$3,600.0012,070View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Predictive Oncology (NASDAQ:POAI)

5.78% of Predictive Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at POAI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Predictive Oncology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/13/2022Renaissance Technologies LLC405,100$0.17M0.0%+2,582.8%0.612%Search for SEC Filing on Google Icon
8/11/2022Sax Wealth Advisors LLC107,437$44K0.0%N/A0.162%Search for SEC Filing on Google Icon
7/14/2022RB Capital Management LLC159,500$65K0.0%N/A0.241%Search for SEC Filing on Google Icon
5/17/2022Virtu Financial LLC67,145$66K0.0%N/A0.101%Search for SEC Filing on Google Icon
5/13/2022Charles Schwab Investment Management Inc.55,193$54K0.0%N/A0.084%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.160,629$0.21M0.0%+12.9%0.246%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD106,200$0.14M0.0%N/A0.162%Search for SEC Filing on Google Icon
8/16/2021State Street Corp298,632$0.39M0.0%N/A0.457%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC414,705$0.54M0.0%+198.4%0.635%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.1,838,085$2.41M0.0%+231.9%2.813%Search for SEC Filing on Google Icon
8/12/2021Private Advisor Group LLC26,805$35K0.0%+84.0%0.041%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC82,810$100K0.0%N/A0.166%Search for SEC Filing on Google Icon
5/17/2021Armistice Capital LLC2,051,284$2.48M0.1%N/A4.117%Search for SEC Filing on Google Icon
5/17/2021Goldman Sachs Group Inc.164,258$0.20M0.0%N/A0.330%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC593,267$0.72M0.0%N/A1.191%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp37,348$45K0.0%N/A0.075%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp67,289$81K0.0%+343.4%0.135%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC138,973$0.17M0.0%N/A0.279%Search for SEC Filing on Google Icon
5/11/2021Maryland Capital Management46,000$56K0.0%N/A0.092%Search for SEC Filing on Google Icon
8/14/2020Sabby Management LLC223,540$0.37M0.1%N/A1.541%Search for SEC Filing on Google Icon
8/12/2020Bank of New York Mellon Corp49,449$81K0.0%+191.7%0.341%Search for SEC Filing on Google Icon
8/7/2020Virtu Financial LLC22,668$37K0.0%N/A0.156%Search for SEC Filing on Google Icon
7/17/2020Csenge Advisory Group17,500$29K0.0%N/A0.133%Search for SEC Filing on Google Icon
5/6/2020Bank of New York Mellon Corp16,953$27K0.0%N/A0.274%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.155,934$0.12M0.0%N/A0.508%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Predictive Oncology logo
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Read More on Predictive Oncology

Today's Range

Now: $0.40
Low: $0.39
High: $0.40

50 Day Range

MA: $0.41
Low: $0.36
High: $0.49

52 Week Range

Now: $0.40
Low: $0.25
High: $1.47

Volume

632 shs

Average Volume

590,601 shs

Market Capitalization

$31.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of Predictive Oncology?

Predictive Oncology's top insider investors include:
  1. Carl I Schwartz (CEO)
  2. Charles Lee Sr Nuzum Sr (Director)
  3. J Melville Engle (Director)
  4. Daniel E Handley (Director)
  5. Robert L Myers (CFO)
Learn More about top insider investors at Predictive Oncology.

Who are the major institutional investors of Predictive Oncology?

Predictive Oncology's top institutional investors include:
  1. Renaissance Technologies LLC — 0.61%
  2. RB Capital Management LLC — 0.24%
  3. Sax Wealth Advisors LLC — 0.16%
Learn More about top institutional investors of Predictive Oncology stock.

Which major investors are buying Predictive Oncology stock?

In the last quarter, POAI stock was bought by institutional investors including:
  1. Renaissance Technologies LLC
  2. RB Capital Management LLC
  3. Sax Wealth Advisors LLC
Within the previous year, these company insiders have bought Predictive Oncology stock:
  1. Carl I Schwartz (CEO)
  2. Charles Lee Sr Nuzum Sr (Director)
  3. J Melville Engle (Director)
  4. Daniel E Handley (Director)
Learn More investors buying Predictive Oncology stock.